Angiopoietin 2 (Ang - 2) Inhibitor - Pipeline Review - 2019
Firstview Market Insight "Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019" provides an overview of the pipeline landscape for Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019. It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc. These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.
Angiopoietins are Tie2 receptor ligands that play key roles in vascular development, angiogenesis, and remodeling. Angiopoietin-1 (Ang1) tends to stabilize blood vessels and promote vascular maturation . Ang2 is expressed in growing blood vessels and promotes angiogenesis and tumor growth by destabilizing blood vessels. Vascular destabilization may involve Ang2 acting as an inhibitor or partial agonist of Tie2, which opposes the stabilizing action of Ang1 on endothelial cells. Inhibition of Ang2 may promote vessel stability and reduce angiogenesis thus inhibiting tumor progression. Multiple approaches have been used to inhibit Ang2 to explore effects on angiogenesis and tumor growth. Among these are genetic deletion of host-derived Ang2 , neutralization of angiopoietins by soluble Tie2 receptors that function as decoys, selective Ang2-binding aptamers, and antibodies and peptibodies (peptide-Fc fusion proteins) that selectively neutralize the action of Ang2.
Angiopoietin 2 (Ang-2) Inhibitors have been developed for the treatment of pancreatic, lung, colon breast, prostate carcinoma and NSCLC.
In the last four decades the recognition of a tumor’s fundamental need of an expanding blood vessel network for successful development and growth has led to the identification of novel cancer therapeutic targets. As a consequence anti-angiogenic therapy has now become a common therapeutic modality in cancer treatment. However, patients often do not respond to the currently available anti-angiogenic agents or become resistant to them upon prolonged exposure. Thus, the full potential of anti-angiogenic therapy is yet to be realized and alternate modes of angiogenesis inhibition are needed. Ang-2 is commonly upregulated in tumors and in some cancer settings correlates with advanced disease and poor prognosis. As a result Ang-2 has become a desirable therapeutic target and several Ang-2 inhibiting agents are currently in preclinical or clinical development.
Report Overview:
This part of report provides detailed description of mechanism of action which enables the client to understand the landscape of the Angiopoietin 2 (Ang-2) Inhibitor. This report covers the detailed analysis of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Overview:
This report provides extensive scenario and growth prospects of the market. This section includes the graphical representations of the future treatment landscape based on various phases of development including the NDA/BLA Filing, Phase III, Phase II, Phase I, Pre-Clinical and the Discovery. It also includes details of products which have been dormant or discontinued during the trial stages of development.
Drug Profile Overview:
The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.
Clinical Trial Overview:
This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.
Product Development Activity:
This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.
Company Overview:
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
Scope
Angiopoietins are Tie2 receptor ligands that play key roles in vascular development, angiogenesis, and remodeling. Angiopoietin-1 (Ang1) tends to stabilize blood vessels and promote vascular maturation . Ang2 is expressed in growing blood vessels and promotes angiogenesis and tumor growth by destabilizing blood vessels. Vascular destabilization may involve Ang2 acting as an inhibitor or partial agonist of Tie2, which opposes the stabilizing action of Ang1 on endothelial cells. Inhibition of Ang2 may promote vessel stability and reduce angiogenesis thus inhibiting tumor progression. Multiple approaches have been used to inhibit Ang2 to explore effects on angiogenesis and tumor growth. Among these are genetic deletion of host-derived Ang2 , neutralization of angiopoietins by soluble Tie2 receptors that function as decoys, selective Ang2-binding aptamers, and antibodies and peptibodies (peptide-Fc fusion proteins) that selectively neutralize the action of Ang2.
Angiopoietin 2 (Ang-2) Inhibitors have been developed for the treatment of pancreatic, lung, colon breast, prostate carcinoma and NSCLC.
In the last four decades the recognition of a tumor’s fundamental need of an expanding blood vessel network for successful development and growth has led to the identification of novel cancer therapeutic targets. As a consequence anti-angiogenic therapy has now become a common therapeutic modality in cancer treatment. However, patients often do not respond to the currently available anti-angiogenic agents or become resistant to them upon prolonged exposure. Thus, the full potential of anti-angiogenic therapy is yet to be realized and alternate modes of angiogenesis inhibition are needed. Ang-2 is commonly upregulated in tumors and in some cancer settings correlates with advanced disease and poor prognosis. As a result Ang-2 has become a desirable therapeutic target and several Ang-2 inhibiting agents are currently in preclinical or clinical development.
Report Overview:
This part of report provides detailed description of mechanism of action which enables the client to understand the landscape of the Angiopoietin 2 (Ang-2) Inhibitor. This report covers the detailed analysis of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Overview:
This report provides extensive scenario and growth prospects of the market. This section includes the graphical representations of the future treatment landscape based on various phases of development including the NDA/BLA Filing, Phase III, Phase II, Phase I, Pre-Clinical and the Discovery. It also includes details of products which have been dormant or discontinued during the trial stages of development.
Drug Profile Overview:
The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.
Clinical Trial Overview:
This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.
Product Development Activity:
This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.
Company Overview:
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
Scope
- The report provides a competitive landscape of Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019
- The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and end-point status
- The report provides the list of companies which are the most active in the pipeline
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery
- The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action (MoA); route of administration (RoA); Stage of development; clinical trial status; licensing and collaboration details & other developmental activities
- The report features comparative analysis of product profiles based on molecule type; mechanism of action (MoA); route of administration (RoA)
- The report summarizes all the dormant and discontinued pipeline projects
- The report also provides latest news for the past one year
- To identifying prominent players in the Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019treatment landscape
- To determine the drivers; barriers and unmet need in the Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019treatment space
- Gain strategically significant competitor information; analysis; and insights to formulate effective R&D strategies
- Define in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration
1. ANGIOPOIETIN 2 (ANG-2) INHIBITOR OVERVIEW
2. FEATURED NEWS AND PRESS RELEASES, 2018-2019
3. LIST OF COMPANIES DEVELOPING ANGIOPOIETIN 2 (ANG-2) 2019
4. LATE STAGE PRODUCTS (FILED & PHASE III)
4.1. Faricimab: Phase III
4.1.1. Product Description
4.1.2. Research and Development
4.1.3. Product Development Activities
5. MID STAGE PRODUCTS (PHASE II)
5.1. Aflibercept/nesvacumab:
5.1.1. Product Description
5.1.2. Research and Development
5.1.3. Product Development Activities
6. EARLY STAGE PRODUCTS (PHASE I AND IND)
6.1. LY 3207447: Phase I
6.1.1. Product Description
6.1.2. Research and Development
6.1.3. Product Development Activities
7. PRE-CLINICAL AND DISCOVERY PRODUCTS
7.1. LY 3207447
7.1.1. Product Description
7.1.2. Research and Development
7.1.3. Product Development Activities
7.2. ABP 201
7.2.1. Product Description
7.2.2. Research and Development
7.2.3. Product Development Activities
7.3. ABP 200
7.3.1. Product Description
7.3.2. Research and Development
7.3.3. Product Development Activities
8. DRIVERS OF ANGIOPOIETIN 2 (ANG-2) INHIBITOR
9. CONSTRAINTS OF ANGIOPOIETIN 2 (ANG-2) INHIBITOR
10. THERAPEUTIC ASSESSMENT
10.1. Assessment by Route of Administration
10.2. Assessment by Phase & Route of Administration
10.3. Assessment by Molecule Type
10.4. Assessment by Phase & Molecule type
10.5. Assessment by Target
10.6. Assessment by Mechanism of Action
11. COLLABORATIONS AND ACQUISITIONS DETAILS
12. DORMANT PRODUCTS
13. DISCONTINUED PRODUCTS
14. MARKET TRENDS
15. MARKET OPPORTUNITY ASSESSMENT
16. UNMET NEEDS
17. SWOT ANALYSIS
18. APPENDIX
19. REPORT METHODOLOGY
20. CONSULTING SERVICES
21. DISCLAIMER
2. FEATURED NEWS AND PRESS RELEASES, 2018-2019
3. LIST OF COMPANIES DEVELOPING ANGIOPOIETIN 2 (ANG-2) 2019
4. LATE STAGE PRODUCTS (FILED & PHASE III)
4.1. Faricimab: Phase III
4.1.1. Product Description
4.1.2. Research and Development
4.1.3. Product Development Activities
5. MID STAGE PRODUCTS (PHASE II)
5.1. Aflibercept/nesvacumab:
5.1.1. Product Description
5.1.2. Research and Development
5.1.3. Product Development Activities
6. EARLY STAGE PRODUCTS (PHASE I AND IND)
6.1. LY 3207447: Phase I
6.1.1. Product Description
6.1.2. Research and Development
6.1.3. Product Development Activities
7. PRE-CLINICAL AND DISCOVERY PRODUCTS
7.1. LY 3207447
7.1.1. Product Description
7.1.2. Research and Development
7.1.3. Product Development Activities
7.2. ABP 201
7.2.1. Product Description
7.2.2. Research and Development
7.2.3. Product Development Activities
7.3. ABP 200
7.3.1. Product Description
7.3.2. Research and Development
7.3.3. Product Development Activities
8. DRIVERS OF ANGIOPOIETIN 2 (ANG-2) INHIBITOR
9. CONSTRAINTS OF ANGIOPOIETIN 2 (ANG-2) INHIBITOR
10. THERAPEUTIC ASSESSMENT
10.1. Assessment by Route of Administration
10.2. Assessment by Phase & Route of Administration
10.3. Assessment by Molecule Type
10.4. Assessment by Phase & Molecule type
10.5. Assessment by Target
10.6. Assessment by Mechanism of Action
11. COLLABORATIONS AND ACQUISITIONS DETAILS
12. DORMANT PRODUCTS
13. DISCONTINUED PRODUCTS
14. MARKET TRENDS
15. MARKET OPPORTUNITY ASSESSMENT
16. UNMET NEEDS
17. SWOT ANALYSIS
18. APPENDIX
19. REPORT METHODOLOGY
20. CONSULTING SERVICES
21. DISCLAIMER
LIST OF TABLES
Table 1: Marketed and Pipeline Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019 drugs, 2019
Table 2: Sales of Marketed drugs, 2019
Table 3: Patent expiration details – marketed drugs, 2019
Table 4: Number of Products Under Development for Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019, 2019
Table 5: Products under Development by Companies, 2019
Table 6: Late Stage Products, 2019
Table 7: Mid Stage Products, 2019
Table 8: Early Stage Products, 2019
Table 9: Pre-Clinical and Discovery Products, 2019
Table 10: Assessment by Route of Administration, 2019
Table 11: Assessment by Stage and Route of Administration, 2019
Table 12: Assessment by Molecule Type, 2019
Table 13: Assessment by Stage and Molecule Type, 2019
Table 14: Assessment by Target, 2019
Table 15: Assessment by Mechanism of Action, 2019
Table 16: Dormant Products, 2019
Table 17: Discontinued Products, 2019
Table 1: Marketed and Pipeline Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019 drugs, 2019
Table 2: Sales of Marketed drugs, 2019
Table 3: Patent expiration details – marketed drugs, 2019
Table 4: Number of Products Under Development for Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019, 2019
Table 5: Products under Development by Companies, 2019
Table 6: Late Stage Products, 2019
Table 7: Mid Stage Products, 2019
Table 8: Early Stage Products, 2019
Table 9: Pre-Clinical and Discovery Products, 2019
Table 10: Assessment by Route of Administration, 2019
Table 11: Assessment by Stage and Route of Administration, 2019
Table 12: Assessment by Molecule Type, 2019
Table 13: Assessment by Stage and Molecule Type, 2019
Table 14: Assessment by Target, 2019
Table 15: Assessment by Mechanism of Action, 2019
Table 16: Dormant Products, 2019
Table 17: Discontinued Products, 2019
LIST OF FIGURES
Figure 1: Marketed and Pipeline Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019 drugs, 2019
Figure 2: Sales of Marketed drugs, 2019
Figure 3: Patent expiration details – marketed drugs, 2019
Figure 4: Number of Products Under Development for Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019, 2019
Figure 5: Products under Development by Companies, 2019
Figure 6: Late Stage Products, 2019
Figure 7: Mid Stage Products, 2019
Figure 8: Early Stage Products, 2019
Figure 9: Pre-Clinical and Discovery Products, 2019
Figure 10: Assessment by Route of Administration, 2019
Figure 11: Assessment by Stage and Route of Administration, 2019
Figure 12: Assessment by Molecule Type, 2019
Figure 13: Assessment by Stage and Molecule Type, 2019
Figure 14: Assessment by Target, 2019
Figure 15: Assessment by Mechanism of Action, 2019
Figure 16: Dormant Products, 2019
Figure 17: Discontinued Products, 2019
Figure 1: Marketed and Pipeline Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019 drugs, 2019
Figure 2: Sales of Marketed drugs, 2019
Figure 3: Patent expiration details – marketed drugs, 2019
Figure 4: Number of Products Under Development for Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Review-2019, 2019
Figure 5: Products under Development by Companies, 2019
Figure 6: Late Stage Products, 2019
Figure 7: Mid Stage Products, 2019
Figure 8: Early Stage Products, 2019
Figure 9: Pre-Clinical and Discovery Products, 2019
Figure 10: Assessment by Route of Administration, 2019
Figure 11: Assessment by Stage and Route of Administration, 2019
Figure 12: Assessment by Molecule Type, 2019
Figure 13: Assessment by Stage and Molecule Type, 2019
Figure 14: Assessment by Target, 2019
Figure 15: Assessment by Mechanism of Action, 2019
Figure 16: Dormant Products, 2019
Figure 17: Discontinued Products, 2019
